Core Viewpoint - Promis Neurosciences (NASDAQ: PMN) is highlighted due to a price target of $18 set by H.C. Wainwright, indicating a potential price increase of approximately 50.5% from its current trading price of $7.21 [1][5] Group 1: Analyst Ratings - The stock has an average rating of "Moderate Buy" from four brokerages, with one sell rating and three buy ratings [2] - Recent analyst reports show a range of opinions, with Wall Street Zen downgrading the stock to "strong sell" and Weiss Ratings reaffirming a "sell (e+)" rating, while H.C. Wainwright and Guggenheim maintained "buy" ratings [3][5] Group 2: Stock Performance - PMN is currently priced at $7.08, reflecting an increase of approximately 4.86% or $0.33, with a trading range today between $6.51 and $7.40 [4] - Over the past year, PMN has experienced a high of $39.75 and a low of $6.27, with a market capitalization of around $9.25 million and a trading volume of 45,812 shares on NASDAQ [4]